Migraine Therapeutics Market
Migraine Therapeutics Market Scope: Industry
Analysis, Market Size, Growth, Trends Till 2031
Request Sample Report
Migraine Therapeutics Market Size and Growth
The global migraine therapeutics market is projected to reach a value of $8.3 billion by 2027, with a compound annual growth rate of 4.8%. Rising prevalence of migraines, increased awareness of treatment options, and advancements in drug development are driving market growth. Key players in the market include Eli Lilly, Novartis, and Teva Pharmaceuticals.
Request Sample Report
Companies Covered
(Covid 19 Impact Covered)
◍ Allergan
◍ Merck
◍ Pfizer
◍ Teva
◍ Amgen
◍ Johnson & Johnson
◍ Endo International
◍ GlaxoSmithKline
◍ Impax
◍ Abbott
◍ Bayer
◍ Eli Lilly
◍ Novartis International
◍ Ethypharm
◍ Kowa Pharmaceuticals America
◍ Winston Pharmaceuticals
◍ AstraZeneca
- Competitive landscape: Allergan, Merck, Pfizer, Teva, Amgen, Johnson & Johnson, Endo International, GlaxoSmithKline, Impax, Abbott, Bayer, Eli Lilly, Novartis International, Ethypharm, Kowa Pharmaceuticals America, Winston Pharmaceuticals, AstraZeneca, Amirall, OptiNose, Revance Therapeutics, RedHill Biopharma, Bausch Health, NeurAxon, Biohaven Pharma, Eisai, Valeant Pharma.
- Companies use migraine therapeutics market through research, development, and marketing of drugs targeting migraine treatment.
- Sales revenue: Allergan ($15.8 billion), Pfizer ($49.6 billion), Amgen ($23.7 billion).
◍ Amirall
Request Sample Report
Market Segmentation
By Application
◍ Clinics
◍ Household Use
By Product
◍ Other ◍ Hospitals
◍ Specific Anti-migraine Drugs
◍ Acute Therapies
◍ Preventative Therapies
◍ Others
Request Sample Report
Market Growth
Request Sample Report
$ 0.94 Billion
THANK YOU Email : sales@reportprime.com USA : +1 507 500 7209 Website : https://www.reportprime.com/ Request Sample Report Contact US Our Clients